Press Releases

Year

December 27, 2018

Osmotica Pharmaceuticals Appoints Seasoned Financial Executive Gregory Cowan to Board of Directors and Audit Committee

BRIDGEWATER, N.J. , Dec. 27, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Gregory Cowan , a seasoned financial executive with almost 40 years of experience will join the

December 3, 2018

Osmotica Pharmaceuticals to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

BRIDGEWATER, N.J. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison , Chief Executive Officer, and Andrew Einhorn , Chief Financial Officer, will present at

November 8, 2018

Osmotica Pharmaceuticals plc Reports Third Quarter 2018 Results

BRIDGEWATER, N.J. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2018 .

November 5, 2018

Osmotica Pharmaceuticals plc to Discuss Third Quarter 2018 Financial Results on November 8, 2018

BRIDGEWATER, N.J. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2018 third quarter financial results on Thursday, November 8, 2018 , after

October 22, 2018

Osmotica Pharmaceuticals plc Announces Closing of Initial Public Offering

BRIDGEWATER, N.J., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc, a fully integrated biopharmaceutical company, today announced the closing of its initial public offering of 7,647,500 ordinary shares at a public offering price of $7.00 per share.

October 17, 2018

Osmotica Pharmaceuticals plc Announces Pricing of Initial Public Offering

BRIDGEWATER, N.J., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc, a fully integrated biopharmaceutical company, today announced the pricing of its initial public offering of 6,650,000 ordinary shares at a public offering price of $7.00 per share.

February 19, 2018

FDA Approves Osmotica Pharmaceutical’s Once-Daily OSMOLEX ER™ (amantadine) extended-release tablets for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions in Adults

Investor Relations

News

Press Releases

Press Releases

Press Releases